Showing results (2671-2680 of 3,166) with videos related to

Sort By:
Pageof 317
Neuro-Oncology|June 13, 2017
PET imaging in patients with meningioma-report of the RANO/PET GroupNorbert Galldiks, Nathalie L Albert, Michael Sommerauer, et al.
Neuro-Oncology|May 23, 2018
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working GroupNils D Arvold, Terri S Armstrong, Katherine E Warren, et al.
Neuro-Oncology|May 12, 2018
An orthotopic glioblastoma animal model suitable for high-throughput screeningsLinda Pudelko, Steven Edwards, Mirela Balan, et al.
Neuro-Oncology|May 18, 2018
Immunotherapy in CNS cancers: the role of immune cell traffickingNivedita M Ratnam, Mark R Gilbert, Amber J Giles
Neuro-Oncology|July 9, 2018
Copy number profiling across glioblastoma populations has implications for clinical trial designPatrick J Cimino, Lisa McFerrin, Hans-Georg Wirsching, et al.
Neuro-Oncology|July 17, 2018
TERT promoter mutations are associated with poor prognosis and cell immortalization in meningiomaSabine Spiegl-Kreinecker, Daniela Lötsch, Katharina Neumayer, et al.
Neuro-Oncology|June 13, 2018
Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomasMathias Kunz, Nathalie Lisa Albert, Marcus Unterrainer, et al.
Neuro-Oncology|September 1, 2016
A novel 3D human glioblastoma cell culture system for modeling drug and radiation responsesNatividad Gomez-Roman, Katrina Stevenson, Lesley Gilmour, et al.
Neuro-Oncology|April 29, 2017
Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progressionChangbin Zhu, Dana Mustafa, Ping-Pin Zheng, et al.
Neuro-Oncology|May 9, 2017
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patientsChristin Schmidt, Nil A Schubert, Sebastian Brabetz, et al.
Pageof 317